Related Experiment Video
Updated: May 15, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities
Marcelo A Lima1, Christian Viskov, Frederic Herman
1Disciplina de Biologia Molecular, Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, SP, 04044-020, Brazil.
Thrombosis and Haemostasis
|January 19, 2013
Summary
Ultra-low-molecular-weight heparins (ULMWHs) show structural differences from enoxaparin, impacting anticoagulant activity. Understanding these features aids in developing improved heparin-based antithrombotic therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Development of ultra-low-molecular-weight heparins (ULMWHs) aims for improved efficacy and safety.
- Limited structural data currently exists for these advanced heparin derivatives.
Purpose of the Study:
- To characterize the main structural features and molecular weight of ULMWHs.
- To compare ULMWHs with enoxaparin to understand structure-activity relationships.
Main Methods:
- Monosaccharide composition and average molecular weight determination.
- Analysis using nuclear magnetic resonance spectroscopy, scanning ultraviolet spectroscopy, circular dichroism, and gel permeation chromatography.
Main Results:
- ULMWHs exhibit higher levels of 3-O-sulphated glucosamine and unsaturated uronic acid residues.
- Structural analysis revealed ULMWHs are related to low-molecular-weight heparins (LMWHs) but differ significantly in composition and molecular weight, explaining varied anticoagulant activities.
Conclusions:
- ULMWHs possess distinct structural characteristics compared to LMWHs and enoxaparin.
- These structural insights are crucial for the rational design of novel heparin-based therapeutics for thrombotic disorders.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...